Natural History: HCV symptoms, disease progression and
management..
●
General
o
1612. Relationship of Iron [Fe] and
HFE genetic variations to progression and outcomes of advanced chronic hepatitis
C in the HALT-C Trial.
o
1613. Aging of Hepatitis C Infected
Persons in the United States: A Multiple Cohort Model of HCV Prevalence and
Disease Progression. (updated Nov
5, 2009)
o
1617. Incidence of end-stage liver
disease and death among 585 HIV/HCV coinfected adults according to baseline
fibrosis stage. (updated Nov
5, 2009)
o
1620. Validation of a panel of
genetic markers (CRS7) in predicting cirrhosis, fibrosis progression (FP) and
clinical outcomes in patients with chronic hepatitis C (CHC) in the HALT-C
trial.
o
1622. Insulin Resistance and Hepatic
Steatosis are Both Independently Associated with Advanced Hepatic Fibrosis in
Chronic Hepatitis C Infection: Analysis of the ACHIEVE 1 and ACHIEVE 2/3
Cohorts
o
1625. Serum fibrosis markers are
associated with clinical outcomes and histological progression in patients with
chronic hepatitis C (CHC) and advanced fibrosis.
o
1626. Chronic Hepatitis C Infection
is Associated with Lower Rates of Hospitalization for Coronary Heart Disease.
o
1627. Hepatic Impairment Measured by
Quantitative Tests of Liver Function (QLFTs) Predicts Clinical Outcome in
Patients with Advanced Fibrosis: Results from the Hepatitis C Antiviral
Long-Term Treatment against Cirrhosis (HALT-C) Trial.
o
1650. Long-term evaluation of
fibrosis by Transient Elastography in patients clearing HCV on antiviral therapy.
o
1655. Quantitative HCV core antigen
and HCV-RNA kinetics in HCV infected patients over a period of up to 8 years.
o
1656. The Extent of Liver Fibrosis
Measured Using Transient Elastometry Predicts Mortality in HIV Patients with
Liver Cirrhosis.
o
1657. Amino acid substitutions in the
hepatitis C virus core region were induced by aging and severe hepatic
fibrosis.
o
1658. Semen Characteristics In
Hepatitis C Virus (HCV) Infected Patients. Relationship Between Semen
Characteristics And Assisted Reproduction Technologies (ART) Practice. (updated Nov 5, 2009)
o
1659. Excessive alcohol intake
drastically impacts transplant-free survival: a longitudinal study in HCV
cirrhotic patients (updated Nov
9, 2009)
o
1663. Prediction of HCV-related
mortality in Belgium using a mathematical modeling approach: impact of current
treatment practice and different scenarios improving screening, access to
treatment and treatment efficacy.
o
Acute HCV
§ 1619.
Natural clearance of hepatitis C virus (HCV) RNA in chronic HCV carriers: A
long-term cohort study in an endemic area of HCV infection in Japan.
§ 1662.
Early spontaneous resolution of acute hepatitis C depends on the HCV genotypes
and the levels of HCV RNA.
o
Biopsy
§ 1629.
Paired Biopsies Illustrate Racial Differences in Fibrosis Progression in HCV
Patients.
§ 1630.
Age, Insulin Resistance and Steatosis are Independent Risk Factors for Fibrosis
Progression in Untreated Patients with Mild Chronic Hepatitis C: A Prospective
Study with Repeat Biopsies. (updated Nov 13, 2009)
§ 1639.
Hepatic fibrosis regression in the setting of persistent viremia in chronic
hepatitis C: a dual biopsy study.
§ 1654.
Diagnosis of occult HCV infection without performing a liver biopsy.
o
Quality of Life
§ 1644.
Resilience affects the quality of life in patients with chronic hepatitis C.
(updated Nov 5, 2009)
§ 1645. Self-reported cognitive
symptoms are commonly associated with underlying neurocognitive impairment in
hepatitis C infected patients referred for antiviral treatment. (updated Nov 5, 2009)
o
Women
o
1615. Early loss of exposure to
Estrogens is critical in determining entity of fibrosis and response to IFN in
women with hepatitis C.
o
1631. Hepatitis C and menopause:
interplay of age, gender, HCV replication and activity in progression and
consequence for therapy. (updated Nov 13, 2009)